Expands hospital payment for rare disease biologics

File SF4521 ("Expands hospital payment for rare disease biologics") is before the Minnesota Legislature and has not been decided. Latest step (March 17, 2026): Introduction and first reading.

Minnesota file SF4521, before the Minnesota Legislature. Still to be decided as of 2026-03-17.

What it does

Patients may gain faster access to rare disease treatments If reimbursement rules become more favorable, hospitals are more likely to stock and offer biological products for rare diseases, potentially reducing wait times or geographic access barriers for patients who need them.

The bigger picture

Shifts cost burden between payers and healthcare system Changes to hospital reimbursement formulas typically flow through to insurance premiums, deductibles, and state Medicaid budgets, affecting how costs are distributed across employers, individuals, and public programs.

Official summary

Hospital reimbursement for certain biological products to treat rare diseases provisions modifications

Read the official record for SF4521

See everything up for a vote · This week in Minnesota · See what we have filed with the clerk